[1]李前进,拜合提亚·阿扎提,王文光,等.ST6GalⅠ在肾透明细胞癌中表达及其与病理特征的关系[J].医学信息,2021,34(06):87-89.[doi:10.3969/j.issn.1006-1959.2021.06.022]
　LI Qian-jin,Baihetia Azati,WANG Wen-guang,et al.The Expression of ST6GalⅠ in Renal Clear Cell Carcinoma and Its Relationship with Pathological Features[J].Medical Information,2021,34(06):87-89.[doi:10.3969/j.issn.1006-1959.2021.06.022]
点击复制

ST6GalⅠ在肾透明细胞癌中表达及其与病理特征的关系()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年06期
页码:
87-89
栏目:
论著
出版日期:
2021-03-15

文章信息/Info

Title:
The Expression of ST6GalⅠ in Renal Clear Cell Carcinoma and Its Relationship with Pathological Features
文章编号:
1006-1959（2021）06-0087-03
作者:
李前进; 拜合提亚·阿扎提; 王文光; 等
（新疆医科大学第一附属医院泌尿外科，新疆 乌鲁木齐 830054）
Author(s):
LI Qian-jin; Baihetia Azati; WANG Wen-guang; et al.
(Department of Urology,the First Affiliated Hospital of Xinjiang Medical University,Urumqi 830054,Xinjiang,China)
关键词:
ST6GalⅠ; 肾透明细胞癌; 肿瘤分级; 肿瘤分期
Keywords:
ST6GalⅠ; Renal clear cell carcinoma; Tumor grade; Tumor stage
分类号:
R737.11
DOI:
10.3969/j.issn.1006-1959.2021.06.022
文献标志码:
A
摘要:
目的 探讨人β半乳糖苷α-2，6-唾液酸转移酶Ⅰ（ST6GalⅠ）在肾透明细胞癌（ccRCC）组织及正常肾组织中表达的差异及其与患者病理特征的关系。方法 选择2013年1月~2019年12月来院就诊的ccRCC患者127例作为研究对象，取ccRCC患者癌组织作为研究组，癌旁正常肾组织作为对照组。免疫组化法检测两组ST6GalⅠ的表达，分析其表达与年龄、性别、肿瘤大小、分期及肿瘤分级的关系。结果 免疫组化结果显示，研究组ST6GalⅠ表达水平高于对照组，差异有统计学意义（P＜0.05）；不同年龄、性别的ccRCC组织中ST6GalⅠ的表达比较，差异无统计学意义（P＞0.05）；不同肿瘤分期、大小、分级的ccRCC组织中ST6GalⅠ的表达比较，差异有统计学意义（P＜0.05）。结论 ST6GalⅠ在ccRCC组织中的表达水平高于正常肾脏组织，且肿瘤大小≥7 cm，分期为2期，分级为中低分化的ccRCC患者ST6GalⅠ表达阳性率也较高。
Abstract:
Objective To investigate the differences in the expression of human β-galactoside α-2,6-sialyltransferase I (ST6GalI) in clear cell renal cell carcinoma (ccRCC) tissues and normal renal tissues and its relationship with the pathological characteristics of patients.Methods 127 ccRCC patients who came to the hospital from January 2013 to December 2019 were selected as the research objects. The cancer tissue of ccRCC patients was selected as the research group, and the normal kidney tissue adjacent to the cancer was used as the control group.Immunohistochemical method was used to detect the expression of ST6GalI in the two groups, and the relationship between its expression and age, gender, tumor size, stage and tumor grade was analyzed.Results The results of immunohistochemistry showed that the expression level of ST6GalⅠ in the study group was higher than that in the control group,the difference was statistically significant (P＜0.05);There was no statistically significant difference in the expression of ST6GalⅠ in ccRCC tissues of different ages and genders (P>0.05);There was a statistically significant difference in the expression of ST6GalI in ccRCC tissues of different tumor stages, sizes and grades (P<0.05).Conclusion The expression level of ST6GalI in ccRCC tissues is higher than that in normal kidney tissues, and the tumor size is ≥7 cm, and the stage is stage 2. The positive rate of ST6GalI expression in ccRCC patients with moderate to poor differentiation is also higher.

参考文献/References:

[1]Hsieh CC,Shyr YM,Liao WY,et al.Elevation of β-galactoside α2,6-sialyltransferase 1 in a fructoseresponsivemanner promotes ancreatic cancermetastasis[J].Oncotarget,2017,8(5):7691-7709. [2]Wei A,Fan B,Zhao Y,et al.ST6Gal-I overexpression facilitates prostate cancer progression via the PI3K/Akt/GSK-3β/β-catenin signaling pathway[J].Oncotarget,2016,7(40):65374-65388. [3]Bassaganas S,Allende H,Cobler L,et al.Inflammatory cytokines regulate the expression of glycosyltransferases involved in the biosynthesis of tumor-associated sialylated glycans in pancreatic cancer cell lines[J].Cytokine,2015,75(1):197-206. [4]Agrawal P,Fontanals-Cirera B,Sokolova E,et al.A Systems Biology Approach Identifies FUT8 as a Driver of Melanoma Metastasis[J].Cancer Cell,2017,31(6):804-819. [5]Beatrice W,Karin ML,Vladimir G,et al.Prognostic role of the sialyltransferase ST6GAL1 in ovarian cancer[J].Glycobiology,2018,28(11):898-903. [6]Munkley J.The glycosylation landscape of pancreatic cancer(Review)[J].Oncology letters,2019,17(3):2569-2575. [7]Schult MJ,Holdbrooks AT,Chakrabory A,et al.The Tumor-Associated Glycosyltransferase ST6Gal-I Regulates Stem Cell Transcription Factors and Confers a Cancer Stem Cell Phenotype[J].Cancer Res,2016,76(13):3978-3988. [8]Liu N,Zhu M,Lin HY,et al.Increasing HER2 α2,6 sialylation facilitates gastric cancer progression and resistance via the Akt and ERK pathways[J].OncolRep,2018,40(5):2997-3005. [9]Jones RB,Dorsett KA,Hjelmeland AB,et al.The ST6Gal-I sialyltransferase protects tumor cells against hypoxia by enhancing HIF-1α signaling[J].J Biol Chem,2018,293(15):5659-5667. [10]张涛,木拉提·热夏提,威力江·赛买提,等.肾癌患者手术前后血清蛋白质指纹图谱的变化[J].中华实验外科杂志,2012,29(12):2413-2145. [11]李前进,王玉杰,刘强,等.ST6GalⅠ抑制TNFR1的表达而调控肾透明细胞癌凋亡[J].中国癌症防治杂志,2020,12(4):415-420. [12]Montanari M,Rossetti S,Cavaliere C,et al.Epithelial-mesenchymal transition in prostate cancer: an overview[J].Oncotarget,2017,8(21):35376-35389. [13]Goossens S,Vandamme N,Van Vlierberghe P,et al.EMT transcription factors in cancer development re-evaluated: Beyond EMT and MET[J].Biochim Biophys Acta Rev Cancer,2017,1868(2):584-591. [14]Zhao Y,Li Y,Ma H,et al.Modification of sialylation mediates the invasive properties and chemosensitivity of human hepatocellular carcinoma[J].Mol Cell Proteomics,2014,13(2):520-536. [15]Wang PH,Lee WL,Lee YR,et al.Enhanced expression of alpha 2,6-sialyltransferase ST6Gal I in cervical squamous cell carcinoma[J]. Gynecol Oncol,2003(89):395-401. [16]Hebbar M,Krzewinski-Recchi MA,Hornez L,et al.Prognostic value of tumoral sialyltransferase expression and circulating E-selectin concentrations in node-negative breast cancer patients[J].Int J Biol Markers,2003,18(2):116-122. [17]Lu J,Isaji T,Im S,et al.β-Galactoside α2,6-sialyltranferase 1 promotes transforming growth factor-β-mediated epithelial-mesenchymal transition[J].J Biol Chem,2014,289(50):34627-34641.

相似文献/References:

[1]桂慧慧,刘 霞.基于多数据库分析MYH10在肾透明细胞癌中的表达与意义[J].医学信息,2022,35(10):20.[doi:10.3969/j.issn.1006-1959.2022.10.004]
　GUI Hui-hui,LIU Xia.Expression and Significance of MYH10 in Renal Clear Cell Carcinoma Based on Multi-database Analysis[J].Medical Information,2022,35(06):20.[doi:10.3969/j.issn.1006-1959.2022.10.004]
[2]毛 伟,张 琳,刘清钊.肾透明细胞癌细胞焦亡相关基因预后模型的建立与应用[J].医学信息,2022,35(14):1.[doi:10.3969/j.issn.1006-1959.2022.14.001]
　MAO Wei,ZHANG Lin,LIU Qing-zhao.Constructionand Application of Pyroptosis-related Genes Prognosis Model in Clear Cell Renal Cell Carcinoma[J].Medical Information,2022,35(06):1.[doi:10.3969/j.issn.1006-1959.2022.14.001]
[3]李 松,李瑞杰,赵小磊.CDKN2A基因突变与肾细胞癌药物敏感性和预后的关系[J].医学信息,2022,35(16):1.[doi:10.3969/j.issn.1006-1959.2022.16.001]
　LI Song,LI Rui-jie,ZHAO Xiao-lei.Relationship Between CDKN2A Gene Mutation and Drug Sensitivity and Prognosis of Renal Cell Carcinoma[J].Medical Information,2022,35(06):1.[doi:10.3969/j.issn.1006-1959.2022.16.001]
[4]吴文杰,裴天龙,汪永康,等.基于CT影像组学特征预测肾透明细胞癌分化程度的研究[J].医学信息,2021,34(11):96.[doi:10.3969/j.issn.1006-1959.2021.11.026]
　WU Wen-jie,PEI Tian-long,WANG Yong-kang,et al.Study on Predicting Differentiation Degree of Renal Clear Cell Carcinoma Based on CT Imaging Features[J].Medical Information,2021,34(06):96.[doi:10.3969/j.issn.1006-1959.2021.11.026]
[5]单 丽,朱晓力,向程程,等.基于NUF2mRNA、HAMP mRNA、分期、病理分级及年龄的预后评估模型在肾透明细胞癌预后判断中的运用[J].医学信息,2023,36(09):42.[doi:10.3969/j.issn.1006-1959.2023.09.007]
　SHAN Li,ZHU Xiao-li,XIANG Cheng-cheng,et al.The Application of Prognostic Evaluation Model Based on NUF2mRNA,HAMP mRNA,Stage,Pathological Grade and Age in the Prognosis of Kidney Renal Clear Cell Carcinoma[J].Medical Information,2023,36(06):42.[doi:10.3969/j.issn.1006-1959.2023.09.007]

更新日期/Last Update: 1900-01-01